Topics

FDA grants orphan drug status for cryptococcosis treatment

05:40 EDT 10 Oct 2019 | SmartBrief

Matinas BioPharma's orally administered formulation for its investigational treatment MAT2203, or amphotericin B, as an orall -More

Original Article: FDA grants orphan drug status for cryptococcosis treatment

NEXT ARTICLE

More From BioPortfolio on "FDA grants orphan drug status for cryptococcosis treatment"

Quick Search